"World Cell-Based Assays Market Will Reach 2.78 Billion Dollars in 2012" Says Visiongain Report

LONDON, January 25, 2012 /PRNewswire/ --

A new report by visiongain predicts that the world market for cell-based assays will reach 2.78 billion dollars in 2012. That sales forecast appears in Cell-Based Assays: World Market Prospects 2012-2022, published in January 2012. Visiongain is a business information provider based in London, UK.

Visiongain estimates that in 2011 primary and secondary screening accounted for more than three quarters of cell-based assays used. Most assays used in target validation and lead identification are cell-based assays. Over the coming 10 years, cell-based assays used for toxicity testing will drive market growth. This application accounted for less than 10% of cell-based assay usage in 2010. Human cell-based assays have advantages over animal models for predicting toxicity in human beings.

This study forecasts the future of two submarkets: cell-based assay products and cell-based assay services. In 2010, cell-based assay services accounted for less than a quarter of the total market. As drug developers increasingly use cell-based assays in drug discovery, they will benefit from the expertise of CROs to a greater extent. CROs also offer the advantage of improved time management and greater cost efficiency. The cell-based assay services submarket will expand faster than the overall market, growing with a CAGR of 15.9% to 2016.

Richard Lang, a pharmaceutical industry analyst at visiongain, said: "The technology and equipment for cell-based testing have improved significantly over the past decade. The market will be driven by the automation and miniaturisation of this equipment, allowing cell-based assays to be used more often in high throughput screening. The development of 3D culture techniques will help improve the in vivo predictivity of these assays."

Visiongain's report also analyses nine leading national markets - the US, Japan, the EU5, China and India. In 2010, the US was the world's largest market for cell-based assays. A significant proportion of the world's drug discovery research occurs there, with drug developers keen to adopt new technologies that save time and money. Developed national markets will achieve strong revenue growth to 2022, benefiting from increased uptake of cell-based assays in various drug discovery processes.

Many emerging technologies in cellular testing underpin the use of cell-based assays in pharma R&D. Beyond 3D assay systems, miniaturisation and automation, the greatest driver of revenue growth will be increased use of label-free detection. New systems allow higher throughput, offering greater opportunities for inclusion in drug discovery. Cell-Based Assays: World Market Prospects 2012-2022 adds to visiongain's wide range of analytical reports on industries and markets in healthcare.

To view sample pages please click on:

http://www.visiongain.com/Report/753/Cell-Based-Assays-World-Market-Prospects-2012-2022

1. Executive Summary
1.1 Cell-Based Assays: World Market Review
1.2 Chapter Breakdown
1.3 Research and Analysis Methods
1.4 Scope of this Report

2. An Introduction to Cell-Based Assays
2.1 Drug Discovery and Development
2.1.1 Approaches to Drug Development
2.2 Drug Screening Assays
2.2.1 Animal Models
2.2.2 Biochemical Assays
2.2.3 Uses for Drug Screening Assays
2.2.3.1 Lead Identification
2.2.3.2 Toxicity Testing
2.3 Cell-Based Assays
2.3.1 Assay Format
2.3.2 Assay Detection Technology
2.3.3 Cells Used in a Cell-Based Assay
2.3.3.1 Immortalised Cell Lines
2.3.3.2 Primary Cells
2.3.3.3 Stem Cells
2.3.4 Uses for Cell-Based Assays in Drug Discovery and Development
2.3.4.1 Target Validation
2.3.4.2 Primary Screening
2.3.4.3 Secondary Screening
2.3.4.4 ADME Screening
2.3.4.5 High Throughput Screening

3. The Cell-Based Assays Market 2012-2022
3.1 The Cell-Based Assays Market 2010-2011
3.1.1 The Cell-Based Assays Market by Application, 2010-2011
3.2 The Cell-Based Assays Market Forecast, 2012-2022
3.2.1 The Cell-Based Assays Market as a Share of R&D Spending, 2012-2022
3.3 Outsourced Cell-Based Assay Services Submarket 2010-2011
3.3.1 Outsourced Cell-Based Assay Services Submarket: Revenue Forecast 2012-2022
3.4 Cell-Based Assay Products Submarket 2010-2011
3.4.1 Cell-Based Assay Product Categories
3.4.1.1 Equipment
3.4.1.2 Disposables
3.4.1.3 Consumables
3.4.2 Cell-Based Assay Products Submarket: Revenue Forecast 2012-2022

4. Leading National Cell-Based Assay Markets 2012-2022
4.1 Leading National Markets for Cell-Based Assays 2010-2011
4.2 Leading National Markets: Revenue Forecasts 2012-2022
4.3 The US: Revenues 2012-2022
4.4 Japan: Revenues 2012-2022
4.5 Europe
4.5.1 The European Market: Revenues 2010-2011
4.5.2 The European Market: Revenue Forecasts 2012-2022
4.6 Cell-Based Assays in the Leading Emerging Countries
4.6.1 China: Revenues 2012-2022
4.6.2 India: Revenues 2012-2022

5. Leading Companies in the Cell-Based Assays Market in 2011
5.1 Cell-Based Assay Service Companies
5.1.1 Global CROs
5.1.1.1 Covance
5.1.1.2 PPD
5.1.1.3 Charles River Laboratories
5.1.2 Specialist CROs and Service Companies
5.1.2.1 FluoFarma
5.1.2.2 Marin Biologic Laboratories
5.1.2.3 MD Biosciences
5.2 Cell-Based Assay Product Suppliers
5.3 BD Biosciences
5.3.1 BD Acquires Accuri Cytometers
5.4 Beckman Coulter
5.5 DiscoveRx
5.5.1 DiscoveRx and GPCRs
5.6 EMD Millipore
5.6.1 Expanding in Toxicity Research
5.7 Evotec
5.8 GE Healthcare
5.8.1 GE Healthcare and Stem Cells
5.9 Life Technologies (Invitrogen)
5.10 Molecular Devices
5.11 PerkinElmer
5.11.1 High Content Screening
5.11.2 Caliper Life Sciences
5.11.2.1 Caliper Discovery Alliances and Services
5.12 Promega
5.12.1 Multiplexing Toxicity Testing Tools
5.12.2 Stem Cells
5.13 Sigma-Aldrich
5.13.1 Sigma's ADME-Tox Services
5.14 Thermo Fisher Scientific
5.15 TTP LabTech
5.15.1 Chemotaxis Research

6. Cell-Based Assays: Industry Trends 2012-2022
6.1 Strengths and Weaknesses in the Cell-Based Assays Market 2011
6.1.1 Cell-Based Assays are More Biologically Relevant
6.1.2 Two-Dimensional Cell Assays Have Limitations
6.1.3 An Alternative to Animal Testing
6.2 Opportunities and Threats in the Cell-Based Assays Market 2012-2022
6.2.1 Social Developments
6.2.2 Technological Advances
6.2.3 Economic Pressures
6.2.4 Political Issues
6.3 Stem Cells
6.3.1 The Need for Stem Cells in Cell-Based Assays
6.3.2 Stem Cells Hold Significant Potential
6.3.3 Induced Pluripotent Stem Cells: An Uncontroversial and Abundant Source
6.3.4 Companies Providing Stem Cell Products for the Cell-Based Assay Market
6.3.4.1 Axiogenesis
6.3.4.2 Cellular Dynamics International
6.3.4.3 MultiCell Technologies
6.3.4.4 Stem Cell Innovations
6.4 G-Protein-Coupled Receptors (GPCRs): A Common Drug Discovery Target
6.4.1 The Role of Cell-Based Assays
6.4.2 Allosteric GPCRs Provide a New Approach
6.5 Miniaturisation and Automation
6.5.1 The Demand for Miniaturisation
6.5.2 Microfluidics
6.5.2.1 The Future Potential of Microfluidics
6.5.3 The Trend Towards Automation
6.5.4 Multiplexing: Making Cell-Based Assays More Efficient
6.6 Detection in Cell-Based Assays
6.6.1 High Content Screening (HCS)
6.6.1.1 Future Developments in HCS
6.6.2 Label-Free Technology
6.6.2.1 The Potential of Label-Free Assays
6.6.2.2 CellKey (Molecular Devices)
6.6.2.3 Epic (Corning)
6.6.2.4 xCELLigence (Roche Applied Science/ACEA Biosciences)
6.7 Three-Dimensional Cell-Based Assays: Closer to the True Cellular Environment
6.7.1 Challenges in 3D Cell Culture
6.8 Toxicity Testing: A Key Market for Cell-Based Assays
6.8.1 Alternative Approaches
6.8.2 Restraints on Development
6.8.3 Apredica
6.9 Outsourcing Cell-Based Assays
6.9.1 Why Outsource?
6.10 Growing Interest in Biologics and Biosimilars: A Trend from the Pharmaceutical Industry

7. Research Interviews
7.1 Dr Jan Ehlert, Head of Cellular Drug Discovery, ProQinase
7.1.1 ProQinase
7.1.2 Challenge Facing Cell-Based Assay Use
7.1.3 The Benefits of Using a CRO
7.1.4 Future Advances Set to Benefit Cell-Based Assay Development
7.2 Rob Chaney, General Manager and COO, ReachBio
7.2.1 ReachBio
7.2.2 Cell-Based Assays and Their Application in the Biopharmaceutical Industry
7.2.3 Drivers and Restraints for the Cell-Based Assays Market
7.2.4 The Use of Stem Cells in Cell-Based Assays
7.2.5 The Latest Trends in the Cell-Based Assays Market

8. Conclusions from Our Study
8.1 The Cell-Based Assays Market in 2010-2011
8.2 Outlook for the Cell-Based Assays Market 2012-2022
8.2.1 Regional Outlook for the Market 2012-2022
8.3 Future Opportunities for Cell-Based Assay Developers
8.4 Challenges to be Overcome


Companies Listed

AB SCIEX (a subsidiary of Danaher)
Accuri Cytometers (now part of BD)
ACEA Biosciences
Active Biotech
Advinus Therapeutics
Agennix
Agilent Automation Solutions
APEIRON Biologics
Applied BioPhysics
Apredica (now part of Cyprotex)
AstraZeneca
ATCC (formerly the American Type Culture Collection) [US]
Aurigene Discovery Technologies (a subsidiary of Dr Reddy's Laboratories)
Axiogenesis
BD Biosciences (a division of Becton, Dickinson & Co - BD)
Beckman Coulter (now part of Danaher)
Becton, Dickinson & Co.
BellBrook Labs
Bionas
Biopredic International
BioTek Instruments
BioTime
Boehringer Ingelheim
Boehringer Mannheim
Caliper Discovery Alliances and Services (CDAS, a subsidiary of Caliper Life Sciences)
Caliper Life Sciences (now part of PerkinElmer)
CellCyte Genetics
Cellomics (now part of Thermo Fisher Scientific)
Cellular Dynamics International
Cellumen
Charles River Laboratories
ChemBridge
Codex BioSolutions
Compugen
Corning Life Sciences
Cosmo Bio
Covance
Cubist Pharmaceuticals
Cyprotex
Cytogration
Danaher
Digilab
DiscoveRx
Dr. Reddy's Laboratories
EMD Millipore
Epistem
Eppendorf
European Collection of Cell Culture (ECACC)
European Commission (EC)
European Federation of Pharmaceutical Industries and Associations (EFPIA)
European ScreeningPort
Evotec
Evotec Technologies (a subsidiary of PerkinElmer)
FluoFarma
GE Healthcare (a division of General Electric)
Genentech (part of Roche)
General Electric (GE)
Genospectra
Geron
GSK
Hamilton Robotics
Harvard NeuroDiscovery Center
Harvard University
HD Biosciences
HighRes Biosolutions
Hudson Robotics
IonGate
Jubilant Biosys (a subsidiary of Jubilant Life Sciences)
Jubilant Life Sciences
Labcyte
Leica Microsystems (a subsidiary of Danaher)
Life Technologies
Lonza
Marin Biologic Laboratories
Matrical Bioscience
Maxim Biotech
MD Biosciences
MDS Analytical Technologies (now part of Danaher)
MedImmune
Merck KGaA
Midas Mediscience
Ministry of Education, Culture, Sports, Science and Technology [Japan]
Molecular Devices (a subsidiary of Danaher)
MRC (Medical Research Council) Technology
MultiCell Technologies
Novartis
NovaScreen Biosciences (part of Caliper Life Sciences)
Parexel International
PerkinElmer
Pfizer
Pharmaceutical Research and Manufacturers of America (PhRMA)
PharmaGap
PPD
Promega
ProQinase
Proteome Sciences R&D
PsychoGenics
Puracyp
Q3DM (part of Beckman Coulter)
Quintiles
Radiometer (a subsidiary of Danaher)
ReachBio
Roche
Roche Applied Science (a division of Roche)
Seahorse Bioscience
Sentigen Holding (part of Life Technologies)
Shionogi
Sigma-Aldrich
SRU Biosystems
Stem Cell Innovations
Stemgent
SymCel
TAP Biosystems
Tata Group
Tecan
Thermo Fisher Scientific
TTP LabTech
Tumour Biology Center Freiburg
UCB
University of Kyoto
University of Michigan
University of Tübingen
Veritas
Vitro Biopharma
World Trade Organization (WTO)
Xenogen Biosciences (formerly part of Caliper Life Sciences, acquired by Taconic in 2009)

About visiongain

Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Telecoms, Energy, Pharmaceutical, Defence, Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.

Please contact Sara Peerun for an exec summary:
Email: sara.peerun@visiongainglobal.com
Tel: +44(0)20-7336-6100

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44(0)207-336-6100